Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin-Reference-Cited by-同舟云学术

Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin

Published:2018-10-02 Issue:1 Volume:8 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Nath Kavindra,Roman Jeffrey,Nelson David S.,Guo Lili,Lee Seung-Cheol,Orlovskiy Stepan,Muriuki Kevin,Heitjan Daniel F.,Pickup Stephen,Leeper Dennis B.,Blair Ian A.,Putt Mary E.,Glickson Jerry D.

Funder

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-33019-4.pdf

Reference43 articles.

1. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363, 809–819, https://doi.org/10.1056/NEJMoa1002011 (2010).

2. Ascierto, P. A. et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 17, 1248–1260 https://doi.org/10.1016/S1470-2045(1216)30122-X. Epub32016 Jul 30130. (2016).

3. Larkin, J. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 371, 1867–1876, https://doi.org/10.1056/NEJMoa1408868. Epub1402014 Sep 1408829 (2014).

4. Antonia, S. J., Larkin, J. & Ascierto, P. A. Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects. Clinical Cancer Research 20, 6258–6268, https://doi.org/10.1158/1078-0432.ccr-14-1457 (2014).

5. Mahoney, K. M., Freeman, G. J. & McDermott, D. F. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clinical Therapeutics 37, 764–782, https://doi.org/10.1016/j.clinthera.2015.02.018 (2015).

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lonidamine Increases the Cytotoxic Effect of 1-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-3-(2-chloroethyl)-3-nitrosourea via Energy Inhibition, Disrupting Redox Homeostasis, and Downregulating MGMT Expression in Human Lung Cancer Cell Line;ACS Omega;2024-08-17

2. Energy Blocker Lonidamine Reverses Nimustine Resistance in Human Glioblastoma Cells through Energy Blockade, Redox Homeostasis Disruption, and O⁶-Methylguanine-DNA Methyltransferase Downregulation: In Vitro and In Vivo Validation;ACS Pharmacology & Translational Science;2024-04-17

3. Lonidamine Induced Selective Acidification and De-Energization of Prostate Cancer Xenografts: Enhanced Tumor Response to Radiation Therapy;Cancers;2024-03-31

4. Metabolic Imaging Biomarkers of Response to Signaling Inhibition Therapy in Melanoma;Cancers;2024-01-15

5. A Novel Glycolysis-Related Gene Signature Predicts Prognosis For Cutaneous Melanoma;Combinatorial Chemistry & High Throughput Screening;2023-04